Shares of Iovance Biotherapeutics dropped pre- and post-ASCO without any tangible reasons to point to for the weakness, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The analyst believes news in the TIL arena at ASCO and a recent Nature Medicine publication "only support a key factor" to his investment case. The more solid tumor data using TILs beyond melanoma support continued differentiation versus CAR-Ts, Pantginis contends. The analyst believes the Iovance investment thesis "remains strong" and he keeps a Buy rating on the shares with a $22 price target.